Evidence map›Paper›PMID 38735927›Full record

ReviewJournal of nanobiotechnology2024

Aptamer-functionalized nanomaterials (AFNs) for therapeutic management of hepatocellular carcinoma.

Xiujuan Yin, Jing Rong, Min Shao, Saisai Zhang, Likang Yin, Zhenqiang He, Xiao Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiujuan Yin *Department of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
Jing Rong *Department of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
Min ShaoDepartment of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
Saisai ZhangDepartment of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
Likang YinDepartment of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
Zhenqiang HeClinical Medical College, Hebei University, Baoding, 071002, Hebei, China.
Xiao WangDepartment of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. wangxiao@ahmu.edu.cn.

Funding

Major Research Foundation of Higher Education of Anhui Province 2023AH040370National Natural Science Foundation of China 82370641
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) represents one of the deadliest cancers globally, making the search for more effective diagnostic and therapeutic approaches particularly crucial. Aptamer-functionalized nanomaterials (AFNs), an innovative nanotechnology, have paved new pathways for the targeted diagnosis and treatment of HCC. Initially, we outline the epidemiological background of HCC and the current therapeutic challenges. Subsequently, we explore in detail how AFNs enhance diagnostic and therapeutic efficiency and reduce side effects through the specific targeting of HCC cells and the optimization of drug delivery. Furthermore, we address the challenges faced by AFNs in clinical applications and future research directions, with a particular focus on enhancing their biocompatibility and assessing long-term effects. In summary, AFNs represent an avant-garde therapeutic approach, opening new avenues and possibilities for the diagnosis and treatment of HCC.

Indexed as

Aptamers, NucleotideCarcinoma, HepatocellularLiver NeoplasmsNanostructuresAnimalsAntineoplastic AgentsDrug Delivery SystemsHumansAntineoplastic AgentsAptamers, NucleotideAptamerAptamer-functionalized nanomaterialsHepatocellular carcinomaMolecular imagingTargeted therapy

Identifiers

PMID38735927
PMCPMC11089756

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.